cyrilzakka/clinical-trials huggingface dataset:
UTEROCERVİCAL ANGLE MEASUREMENT IN SPONTANEOUS PRETERM BIRTH (UAMSPB)

İn this study Study; Between August 2018 and August 2019, the Ministry of Health, Medeniyet University, Göztepe Training and Research Hospital, Gynecology and Obstetrics Clinic Will be Included for Routine Control Purposes, Single Pregnancies Between 16-24 Weeks and no Known Risk Factors for Preterm Delivery . Each Participant Will be Given Written and Verbal Information About the Work and Will be Informed. Uterocervical Angle Measurement; Dorsolithotomy, Using a Sterilized Vaginal Ultrasonic Probe. It Will be Seen That the Distance Between the Internal Cervical os and the External Cervical os is Inclusive of the Cervical Isthmus That Can be Seen With the Anterior Uterine Wall. The First Line Will be Drawn Between the Internal Cervical os and the External Cervical os. The Second Line Will be Drawn as Passing Through the Internal Cervical Ostia, Parallel to the Anterior Uterine Wall. The Angle Between the Two Lines on the Internal Cervical Vertebra Will be Measured. Patients Will be Followed up Until the End of the 37th Gestational Week. The Gestation Week They Are Giving Birth Will be Recorded. Patients Were Then Classified as Before and After 37 Gestational Weeks and Uterocervical Angle Measurements Between 16-24 Gestational Weeks Were Compared.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who did not have complaints between December 2017 and August 2018, who went to polyclinic because of routine control
2. Patients who had a pregnancy between 16-24 weeks
3. Patients with singleton pregnancy
4. Patients with a cervical length of 25 mm or more

Exclusion Criteria:

1. Patients with preterm labor history (under 37 weeks) in previous pregnancy
2. Patients with premature rupture of membranes in current pregnancy
3. Patients with past uterine cervical surgery (conization, LEEP) as a cause of premature birth
4. Patients with preterm birth
5. Placenta anomalies present pregnancy
6. Patient with retrovert uterus, uterine fibroid of lower segment
TDCS-Augmented Prolonged Exposure Therapy

The purpose of this study is to determine the effects of a brain stimulation technique known as transcranial direct current stimulation, or tDCS, on the benefits of Prolonged Exposure therapy, or PE, which is an effective treatment for posttraumatic stress disorder, or PTSD. tDCS has been demonstrated to be safe and effective for influencing brain activity by passing a weak electrical current through the scalp. In this study, tDCS is provided in addition to PE treatment, through the National Crime Victim's Research and Treatment Center at MUSC, or the PTSD Clinical Team Clinic within the Ralph H. Johnson VA Medical Center.

This project implements a multiple baseline within-subject clinical trial design aiming to test whether tDCS targeting excitation of the medial prefrontal cortex (mPFC) can enhance a standard course of PE in a sample of adult civilians and Veterans (ages 18-65) who meet full DSM-5 criteria for chronic PTSD (i.e., \> 3 months post-trauma; N = 20). All participants will receive a total of ten 60-min. sessions of manualized PE, preceded by 20 min. of either active or sham HD-tDCS. The stepped-wedge multiple baseline design features tDCS as a 2-level within-subject factor (Sham tDCS+PE vs. Active tDCS+PE), and between-subject comparisons based on stratified random assignment to cross-over from sham to active tDCS just prior to sessions 4 through 8. Strata will be defined by dichotomous classifications of possible confounds, including baseline severity (moderate vs. severe), psychotropic medication status (no vs. yes), and sex (female vs. male). The sample will consist of treatment-seeking civilian and Veteran participants referred by either of two of our consortium sites, including the National Crime Victim's Research and Treatment Center (NCVC) at MUSC, or the PTSD Clinical Team (PCT) at the Ralph H. Johnson VAMC, as well as community participants who respond to study advertisements.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-65.
* Fluent in English.
* Diagnosis of chronic PTSD based on MINI for DSM-5 (\> 3 mo. post-trauma)
* For Veterans recruited at the Ralph H. Johnson VA only: eligible to receive PE in the PCT clinic.

Exclusion Criteria:

* Currently receiving psychotherapy for another anxiety- or stress-related condition.
* Unstable dose of psychotropic medications within 6 weeks prior to baseline assessment
* Medical condition that would contraindicate participation in treatment or assessment activities (e.g., severe cardiovascular problems).
* Pregnancy
* Current severe major depressive disorder
* Current, or history of bipolar disorder
* Current, or history of psychotic symptoms
* Serious suicidal risk
* Active neurological conditions, e.g., seizures, stroke, loss of consciousness or concussion
* Contraindications for tDCS:
* Metal in the head.
* Implanted brain medical devices.
Improving Influenza Vaccination Rates Among Health Care Professionals

The purpose of this study was to see if reminder letters and a large raffle prize would encourage health care workers to receive influenza vaccinations.

Eight hundred employees of an urban tertiary care hospital, 200 each from the following four categories: professional staff, resident physicians, registered nurses, and licensed practical nurses comprised the study group. Subjects were randomly assigned to receive: 1) no intervention, 2) a reminder letter for flu vaccine, 3) a raffle ticket to win a free Caribbean vacation with flu vaccine administration, or 4) both the reminder letter and raffle ticket. We compared the proportion of employees receiving vaccination and participating in the raffle across groups.

Eligibility Criteria:
Inclusion Criteria:

* Hospital employees, staff physicians, residents, rn's, lpn's

Exclusion Criteria:

* non patient care hospital employees
Childhood Reactive Thrombocytosis

Reactive thrombocytosis (RT) in pediatric patients is common, but usually without symptoms. The incidence of RT is different depending on age. Mostly, we reasoned that RT is a phenomenon, nevertheless the diagnostic value of RT is little known. Therefore, the aim of this study was to determine the association of RT and clinical or laboratory characteristics in pediatric diseases.


Eligibility Criteria:
Inclusion Criteria:

* The platelet counts more than 500x109/l and age less than 18 years old.

Exclusion Criteria:

* repeated hospitalization ( more than 2 times)
Study on Early Intra-aortic Balloon Pump Placement in Acute Decompensated Heart Failure Complicated by Cardiogenic Shock

The aim of the study is to demonstrate the superiority of early intra-aortic balloon pump implantation at admission over local clinical practice (pharmacological only) in acute decompensated heart failure patients with cardiogenic shock, with respect to 60-day survival or successful bridge to heart replacement therapies (heart transplant or Left Ventricular Assist Device implantation).

Cardiogenic shock (CS) is the most severe form of acute heart failure, with in-hospital mortality up to 50%. Failure to improve mortality has been reported, despite observed improvements in hemodynamics. Previous studies on CS have almost exclusively been focused on CS following an acute coronary syndrome (ACS). Chronic heart failure patients with acute decompensation (ADHF) and CS represent a unique physiologic phenotype compared with ACS patients, which may lead to a differential response to device therapy. Recent evidences emphasize that intra-aortic balloon pump (IABP) is not recommended for patients with ACS-related CS, but it is associated with a high likelihood of bridge to durable Left Ventricular Assist Device or heart transplant without the need for escalation to more potent temporary mechanical circulatory support devices, when implanted in ADHF patients. Data retrieved from the available literature in the setting of patients with CS not related to ACS are poor even in large, well-reported registries.

Accordingly, Altshock-2 trial has been designed to test the superiority of early IABP implantation at admission over local clinical practice (pharmacological only) in ADHF patients with CS, with respect to 60-day survival or successful bridge to heart replacement therapies

Eligibility Criteria:
INCLUSION CRITERIA

* Age ≥ 18 and \< 75, men and women;
* need of vasoactive agents to maintain SBP \> 90 mmHg or MAP \> 60 mmHg.
* Left ventricle systolic function ≤35%
* SCAI B-D according to CSWG definition (JACC 2022)

EXCLUSION CRITERIA

* septic shock with evident septic focus;
* severe peripheral vascular disease
* CS secondary to cardiac and non-cardiac surgery;
* Acute myocardial infarction within 1 month;
* Suspected or documented myocarditis
* Pulmonary embolism
* Chronic end-stage organ dysfunction that would preclude heart transplant/durable VAD
* ominous prognosis (life expectancy \< 1 year);
* any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
* pregnant, lactating or women planning pregnancy during the course of the trial.
Virtue® Male Sling Fixation Study

This study is a multi-center study that will assess the efficacy and safety of suture fixation of the Virtue® Male Sling.


Eligibility Criteria:
Inclusion Criteria:

* Male subject at least 18 years of age with an estimated life expectancy of of more than 5 years
* The subject has confirmed stress urinary incontinence (SUI) through medical history , urodynamics, and/or physical exam for at least 6 months
* The subject has completed post-void residual per protocol within 6 weeks prior to implant
* The subject has completed cystoscopy as per protocol within 12 months prior to implant
* The subject has intrinsic sphincter deficiency due to one of the following: post-transurethral resection of the prostate (TURP), simple open prostatectomy, or radical prostatectomy completed at least 6 months prior to implantation date
* The subject has failed at least two non-invasive therapies, eg. pelvic/Kegel exercises, behavioral modification or biofeedback for at least 6 months
* The subject is willing to have the Virtue® Male Sling implanted
* The subject is able and willing to complete all follow-up visits and procedures indicated in the protocol
* The subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the local ethics committee of the respective site

Exclusion Criteria:

* The subject is unable or unwilling to sign the informed consent form (ICF)and/or comply with all follow-up requirements according to the study protocol
* The subject has an active urinary tract infection or active skin infection in region of surgery
* The subject has serious bleeding disorders
* The subject has incontinence due to neurogenic causes defined as multiple sclerosis, spinal cord/brain injury, cerebrovascular accident (CVA), detrusor-external sphincter dyssynergia, Parkinson's disease, or similar condition
* The subject had a previous implant to treat stress urinary incontinence
* The subject has undergone radiation, cryosurgery, or brachy therapy to treat prostate or other pelvic cancer within 6 months
* The subject is likely to undergo radiation therapy within the next 6 months
* The subject has active urethral or bladder neck stricture disease requiring continued treatment
* The subject has urge predominant incontinence
* The subject has an atonic bladder or a postvoid residual (PVR) greater than or equal to 150 milliliters (mL)
* The subject has a condition or disorder likely to require future transurethral procedure
* The subject is enrolled in a concurrent clinical study of any treatment (drug or device) that could affect continence function without sponsor's approval
* The subject is deemed unfit for male sling implantation or participation in a research protocol as determined by attending physician
Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency

Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients.

Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients. The parameters that will be measured will include clinical, lab, echo, and quality of life questionnaires.

Eligibility Criteria:
Inclusion Criteria:

* Heart failure grade 3-4
* Heart echo EF\< 40% (ejection fraction)
* Hb \> 10 mg/dL
* Iron\> 50 mic/dL
* Iron/ transferrin rate \> 20%

Exclusion Criteria:

* Infection
* Acute ischemia
* Patients that didn't receive the standard of care during 3 days before investigational product administration
* Hemochromatosis
* Known allergy to one of the products of the investigational product.
* Macrocytic anemia
* Iron excess
* Pregnant women
* Mentally disabled patients which can't give their concent properly.
Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke

To evaluate the efficacy and safety of head acupuncture combined with endovascular therapy for cerebral infarction compared with endovascular therapy alone

Control group: Mechanical thrombectomy followed by the guideline recommended treatment for acute ischemic stroke;

Experimental group: After mechanical thrombectomy, head acupuncture and the treatment regimen recommended by the guideline for acute ischemic stroke were administered

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years;
* Patients with acute ischemic stroke who received endovascular treatment within 24 hours of onset;
* 6 \< NIHSS ≤25;
* ASPECT score ≥6 points;
* Signed Informed consent.

Exclusion Criteria:

* CT or brain MRI confirmed intracranial tumor and intracranial hemorrhage;
* Contraindications of contrast media;
* Dementia or mental illness，unable to cooperate with treatment and follow-up;
* The expected survival time was less than 3 months;
* Women who are pregnant, planning to become pregnant or breastfeeding;
* Currently participating in other clinical trials.
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

The purpose of this study is to assess safety and tolerability of multiple oral doses of GSBR-1290 (capsule) in healthy adult Japanese participants compared to non-Japanese participants.

This is a multiple ascending dose (MAD) study in which 4 dose levels will be evaluated in 2 cohorts from Day 1 to Day 28 (4-week period). The starting dose of GSBR-1290 will be based on results from the single ascending dose (SAD) study (GSBR-1290-01) and MAD study (GSBR-1290-02 \[NCT05762471\]).

Eligibility Criteria:
Inclusion Criteria:

For Cohort 1 only:

1. Japanese participants must have both parents and 4 grandparents of Japanese origin

   For Cohort 2 only:
2. Non-Japanese participants must not have parents and grandparents of Japanese origin. Non-Japanese participants will be limited to Caucasians of European and Latin American descent or African Americans

   For Cohorts 1 and 2:
3. Must have given written informed consent before any study-related activities are carried out
4. Adult males and females, age 18 to 55 years of age (inclusive) at screening
5. Body Mass Index (BMI) greater than or equal to (\>=) 18.5 and less than or equal to (\<=) 24.9 kilogram per square meter (kg/m\^2), with a body weight (to 1 decimal place) \>= 45.0 kg at screening
6. No nicotine use
7. Sitting blood pressure after resting for 5 minutes between 90 to 140 millimeter of mercury (mm Hg) systolic and 50 to 90 mm Hg diastolic and a heart rate between 40 to 100 beats per minute
8. Have suitable venous access for blood sampling

Exclusion Criteria:

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, or neurological disease, including any acute illness or major surgery within the past 3 months
2. Liver function test results elevated \> 2.0-fold the upper limit of normal (ULN) for gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), aspartate transaminase (AST) or alanine transaminase (ALT). Bilirubin above ULN
3. Estimated glomerular filtration rate (eGFR) \< 60 milliliter per minute (mL/min)/1.73m\^2 body surface area
4. Known hypersensitivity to any of the study drug ingredients
5. Any other condition or prior therapy that would make the participant unsuitable for this study
EVALUATING THE EFFICIENCY OF BREATHING EXERCISES PERFORMED BY POST-COVID TELEMEDICINE: Randomized Controlled Study

As an important non-drug intervention in the treatment of respiratory tract diseases, respiratory rehabilitation training is increasingly accepted in clinical practice. The purpose of pulmonary rehabilitation is not only to improve the physical and mental conditions of the patient, but also to help the patient return to the family and society more quickly.

In light of the widely documented lung injuries associated with COVID-19, concerns are raised regarding the assessment of lung injury in discharged patients. As an important non-drug intervention in the treatment of respiratory diseases, respiratory rehabilitation training is increasingly being accepted in clinical practice The purpose of pulmonary rehabilitation is not only to improve the physical and mental conditions of the patient, but also to help the patient return to the family and society more quickly.

The aim of the study; It is aimed to evaluate the efficiency of breathing exercise in individuals with COVID-19.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older and who received / will receive treatment with the diagnosis of COVID 19 and completed 2 months after the diagnosis of COVID 19
* Patients who applied to the Pulmonary Diseases outpatient clinic with complaints of dyspnea
* FEV1 / FVC \<80%, FVC \<80%, FEV1 \<80%, FEF25-75\> 50% and / or Patients with respiratory distress in daily living activities

Exclusion Criteria:

* FEV 1 \<50%, FEF 25-75 \<50% detected oxygen saturation \<85% at rest,
* moderately severe heart failure,
* has a disease that restricts its mobilization,
* psychiatric illness,
* advanced stage liver, advanced stage renal failure,
* Myocardial infarction within 4 months
* having a history of unstable angina
* active infectious disease
Targeted Biopsy or Standard Biopsy for Clinical Significant Prostate Cancer Detection

This randomized controlled trial aims to assess the detection rate of clinically significant and clinically insignificant cancer of mpMRI-targeted biopsy compared to transperineal standard biopsy in men with clinical suspicion of prostate cancer who had no prior prostate biopsy.

Prostate biopsy with multiple samples using a standardized template (standard biopsy, SB) under transrectal ultrasound (TRUS) guidance is the current standard diagnostic approach in suspicion of prostate cancer (PCa). However, many biopsies are unnecessary or cannot detect clinically significant PCa (csPCa).

With the introduction of multiparametric magnetic resonance imaging (mpMRI) of the prostate and the improvement for PCa detection and localization, an alternative procedure, known as MRI-targeted biopsy (TB), has been shown comparable or even higher detection rates of csPCa compared to TRUS-biopsy (SB).

This randomized controlled trial aims to assess the detection rate of clinically significant and clinically insignificant cancer of TB compared to SB (transperineal) in men referred with clinical suspicion of prostate cancer who have had no prior prostate biopsy.

Eligibility Criteria:
Inclusion Criteria:

1. Men more than 18 years old with clinical suspicion of prostate cancer;
2. Serum PSA ≤ 20 ng/ml within the previous 3 months;
3. Suspected stage ≤ T2 on rectal examination (organ-confined prostate cancer) within the previous 3 months;
4. No evidence of PSA increase by noncancerous factors, such as catheterization, bladder stones, or urinary tract infection including bacterial prostatitis;
5. mpMRI PI-RADS V2 score 4 or 5；
6. Able to provide written informed consent.

Exclusion Criteria:

1. Prior prostate biopsy or prostate surgery;
2. Prior treatment for prostate cancer;
3. Contraindication to MRI (e.g. claustrophobia, pacemaker, estimated glomerular filtration rate ≤ 50mls/min);
4. Contraindication to prostate biopsy.
Objective EEG Bed Side Assessment of Impaired Conscious Awareness in Epilepsy

In this project EEG recordings between healthy participants and those with a diagnosed Absence-epilepsy will be compared. The investigators suggest differences in EEG microstate analysis and neuropsychological parameters related to interictal cognitive impairment in these patients. This projects goal is to derive an EEG-based measure of conscious awareness.

This projects goal is to derive an EEG-based measure of conscious awareness to be applied in the care for epilepsy patients. The established terminology of "ictal" versus "interictal" is deceptive because it suggests that during the "interictal" phase epileptic activity is absent and detrimental mechanisms of the disease are only active during seizures. But evidence exists that cognitive impairment extends to states traditionally considered interictal. The development of an objective, ideally ambulatory test assessing cognitive impairment would not only provide a deeper understanding of the pathology but induce a change in clinical practice: if cognitive impairment could be demonstrated "interictally", this fact would help to weigh treatment effects against potential side-effects.

In this project the investigators will set out to

1. identify EEG markers in healthy volunteers, which reflect the changes in spatial and temporal dynamics of neuronal activity during states of reduced conscious awareness using sleep as an example of a state of reduced conscious awareness;
2. assess with neuropsychological testing reductions in interictal conscious awareness in patients with epilepsy;
3. test, whether markers established under (1) are valid in individuals with epilepsy and interictally reduced conscious awareness (see (2)).

Eligibility Criteria:
Inclusion Criteria:

* age minimum 18 years
* diagnosis of (absence) epilepsy // healthy age-matched controls
* being of good health (besides epilepsy in the case group)

Exclusion Criteria:

* central nervous system disorders (besides epilepsy in the case group)
* substance abuse
* pregnancy